Key Points
- Major shareholder Endurance (Cayman) Ltd SVF sold 61,493 Vir Biotechnology shares on Nov. 28 at an average price of $6.44 for about $396,015, leaving it with 13,920,778 shares (a 0.44% reduction) as disclosed to the SEC.
- The sale is part of a broader liquidation: SVF sold roughly 1.2 million shares of VIR across multiple transactions in October–November, totaling several million dollars in proceeds.
- Context: VIR stock is down 5.5%, has a market cap of about $844 million, and recently reported a significant earnings miss (EPS -$1.17 vs. -$0.70 consensus) amid very low revenue, though analysts’ consensus rating is a “Moderate Buy” with a $17.30 target.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 61,493 shares of the company's stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $6.44, for a total value of $396,014.92. Following the transaction, the insider directly owned 13,920,778 shares of the company's stock, valued at $89,649,810.32. This represents a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Endurance (Cayman) Ltd Svf also recently made the following trade(s):
- On Wednesday, November 26th, Endurance (Cayman) Ltd Svf sold 127,938 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.39, for a total value of $817,523.82.
- On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.38, for a total value of $1,505,494.98.
- On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total transaction of $1,400,988.45.
- On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.49, for a total transaction of $649.00.
- On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total transaction of $158,944.50.
- On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $401,738.15.
- On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total transaction of $278,308.16.
- On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.99, for a total value of $924,754.17.
- On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total value of $887,235.90.
- On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.30, for a total value of $690,952.50.
Vir Biotechnology Stock Down 5.5%
VIR stock opened at $6.07 on Tuesday. The company has a market cap of $844.46 million, a price-to-earnings ratio of -1.68 and a beta of 1.34. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The business has a 50 day moving average price of $5.77 and a two-hundred day moving average price of $5.32.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the prior year, the company earned ($1.56) EPS. The company's revenue for the quarter was up .8% on a year-over-year basis. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have commented on VIR shares. Bank of America upgraded shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and increased their price target for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. Evercore ISI initiated coverage on shares of Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $12.00 target price for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Vir Biotechnology in a report on Monday, November 24th. Finally, HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.30.
Read Our Latest Stock Analysis on VIR
Institutional Trading of Vir Biotechnology
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in Vir Biotechnology in the 2nd quarter valued at about $35,000. Federated Hermes Inc. boosted its holdings in shares of Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock worth $46,000 after acquiring an additional 4,899 shares during the period. Apollon Wealth Management LLC acquired a new position in shares of Vir Biotechnology in the second quarter valued at approximately $50,000. PNC Financial Services Group Inc. increased its stake in shares of Vir Biotechnology by 26.2% during the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company's stock worth $68,000 after purchasing an additional 2,171 shares during the period. Finally, FORA Capital LLC bought a new position in shares of Vir Biotechnology during the first quarter worth approximately $70,000. Institutional investors own 65.32% of the company's stock.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
